Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma

NCT03817853 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03817853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03817853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
February 26, 2019
Completion date
January 25, 2023
Enrollment
114 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

advanced follicular lymphoma